Keros Therapeutics (KROS) Tax Provisions (2020 - 2025)
Keros Therapeutics posted quarterly Tax Provisions of -$1.5 million for Q4 2025, down 604.67% year-on-year from $300000.0 in Q4 2024, and down 6.32% on a QoQ basis from -$1.4 million in Q3 2025.
Keros Therapeutics (KROS) has 4 years of Tax Provisions data on file, last reported at -$1.5 million in Q4 2025.
- For the quarter ending Q4 2025, Tax Provisions fell 604.67% year-over-year to -$1.5 million; the trailing twelve-month figure through Dec 2025 stood at $4.9 million (up 1527.67% YoY), and the FY2025 full-year result was $4.9 million, up 1527.67% from the prior year.
- Tax Provisions for Q4 2025 stood at -$1.5 million, down from -$1.4 million in the prior quarter.
- Across five years, Tax Provisions topped out at $10.0 million in Q1 2025 and bottomed at -$2.2 million in Q2 2025.
- The 3-year median for Tax Provisions is $6000.0 (2021), against an average of $899250.0.
- The widest annual swing landed in 2021, when Tax Provisions surged 129.07%; it then sank 604.67% in 2025.
- A 3-year view of Tax Provisions shows it stood at $2.0 million in 2021, then sank by 84.99% to $300000.0 in 2024, then tumbled by 604.67% to -$1.5 million in 2025.
- The last three Tax Provisions figures came in at -$1.5 million (Q4 2025), -$1.4 million (Q3 2025), and -$2.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -11.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 221.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 216,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.66 Mn |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | -1.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.51 Mn |
| Sep 30, 2025 | -1.42 Mn |
| Jun 30, 2025 | -2.22 Mn |
| Mar 31, 2025 | 10.04 Mn |
| Dec 31, 2024 | 300,000.00 |
| Dec 31, 2021 | 2.00 Mn |
| Sep 30, 2021 | -38,000.00 |
| Mar 31, 2021 | 50,000.00 |
| Mar 31, 2020 | -172,000.00 |